GSK slides after buying cancer firm Tesaro for hefty $5.1 billion

GSK has lagged rivals in recent years in producing multibillion-dollar blockbusters and it largely sat out a spate of dealmaking by rival drugmakers under previous CEO Andrew Witty. That is a situation Walmsley wants to change.

Original source: https://health.economictimes.indiatimes.com/news/pharma/gsk-slides-after-buying-cancer-firm-tesaro-for-hefty-5-1-billion/66929563?utm_source=RSS&utm_medium=ETRSS

Related Posts